Guangzhou Innogen Pharmaceutical Group Co Ltd Class H

As of December 31, 2025, Guangzhou Innogen Pharmaceutical Group Co Ltd Class H carries a market capitalization of 12.88B, placing it among publicly traded companies globally. Its enterprise value stands at 11.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Guangzhou Innogen Pharmaceutical Group Co Ltd Class H's next confirmed earnings release is scheduled for March 22, 2027.

As of December 31, 2025, Guangzhou Innogen Pharmaceutical Group Co Ltd Class H has 420.29M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Guangzhou Innogen Pharmaceutical Group Co Ltd Class H maintains a current ratio of 2.93, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Guangzhou Innogen Pharmaceutical Group Co Ltd Class H's stock has declined approximately 90.48% over the past 52 weeks. The 50-day moving average sits at 4.02, while the 200-day moving average is 14.44.

As of December 31, 2025, Guangzhou Innogen Pharmaceutical Group Co Ltd Class H holds 1.34B in cash and equivalents against 185.02M in total debt, resulting in a net debt position of -911.52M. Total book value stands at 1.17B, with working capital of 1.08B providing operational flexibility.